Abstract
In 2020, 146,063 deaths due to pancreatic cancer are estimated to occur in Europe and the United States combined. To identify common susceptibility alleles, we performed the largest pancreatic cancer GWAS to date, including 9040 patients and 12,496 controls of European ancestry from the Pancreatic Cancer Cohort Consortium (PanScan) and the Pancreatic Cancer Case-Control Consortium (PanC4). Here, we find significant evidence of a novel association at rs78417682 (7p12/TNS3, P = 4.35 × 10-8). Replication of 10 promising signals in up to 2737 patients and 4752 controls from the PANcreatic Disease ReseArch (PANDoRA) consortium yields new genome-wide significant loci: Rs13303010 at 1p36.33 (NOC2L, P = 8.36 × 10-14), rs2941471 at 8q21.11 (HNF4G, P = 6.60 × 10-10), rs4795218 at 17q12 (HNF1B, P = 1.32 × 10-8), and rs1517037 at 18q21.32 (GRP, P = 3.28 × 10-8). rs78417682 is not statistically significantly associated with pancreatic cancer in PANDoRA. Expression quantitative trait locus analysis in three independent pancreatic data sets provides molecular support of NOC2L as a pancreatic cancer susceptibility gene.
Original language | English |
---|---|
Article number | 556 |
Journal | Nature Communications |
Volume | 9 |
Issue number | 1 |
DOIs | |
Publication status | Published - 1 Dec 2018 |
Fingerprint
Dive into the research topics of 'Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Nature Communications, Vol. 9, No. 1, 556, 01.12.2018.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer
AU - Klein, Alison P.
AU - Wolpin, Brian M.
AU - Risch, Harvey A.
AU - Stolzenberg-Solomon, Rachael Z.
AU - Mocci, Evelina
AU - Zhang, Mingfeng
AU - Canzian, Federico
AU - Childs, Erica J.
AU - Hoskins, Jason W.
AU - Jermusyk, Ashley
AU - Zhong, Jun
AU - Chen, Fei
AU - Albanes, Demetrius
AU - Andreotti, Gabriella
AU - Arslan, Alan A.
AU - Babic, Ana
AU - Bamlet, William R.
AU - Beane-Freeman, Laura
AU - Berndt, Sonja I.
AU - Blackford, Amanda
AU - Borges, Michael
AU - Borgida, Ayelet
AU - Bracci, Paige M.
AU - Brais, Lauren
AU - Brennan, Paul
AU - Brenner, Hermann
AU - Bueno-De-Mesquita, Bas
AU - Buring, Julie
AU - Campa, Daniele
AU - Capurso, Gabriele
AU - Cavestro, Giulia Martina
AU - Chaffee, Kari G.
AU - Chung, Charles C.
AU - Cleary, Sean
AU - Cotterchio, Michelle
AU - Dijk, Frederike
AU - Duell, Eric J.
AU - Foretova, Lenka
AU - Fuchs, Charles
AU - Funel, Niccola
AU - Gallinger, Steven
AU - Gaziano, J. Michael M.
AU - Gazouli, Maria
AU - Giles, Graham G.
AU - Giovannucci, Edward
AU - Goggins, Michael
AU - Goodman, Gary E.
AU - Goodman, Phyllis J.
AU - Hackert, Thilo
AU - Haiman, Christopher
AU - Hartge, Patricia
AU - Hasan, Manal
AU - Hegyi, Peter
AU - Helzlsouer, Kathy J.
AU - Herman, Joseph
AU - Holcatova, Ivana
AU - Holly, Elizabeth A.
AU - Hoover, Robert
AU - Hung, Rayjean J.
AU - Jacobs, Eric J.
AU - Jamroziak, Krzysztof
AU - Janout, Vladimir
AU - Kaaks, Rudolf
AU - Khaw, Kay Tee
AU - Klein, Eric A.
AU - Kogevinas, Manolis
AU - Kooperberg, Charles
AU - Kulke, Matthew H.
AU - Kupcinskas, Juozas
AU - Kurtz, Robert J.
AU - Laheru, Daniel
AU - Landi, Stefano
AU - Lawlor, Rita T.
AU - Lee, I. Min
AU - Lemarchand, Loic
AU - Lu, Lingeng
AU - Malats, Núria
AU - Mambrini, Andrea
AU - Mannisto, Satu
AU - Milne, Roger L.
AU - Mohelníková-Duchoňová, Beatrice
AU - Neale, Rachel E.
AU - Neoptolemos, John P.
AU - Oberg, Ann L.
AU - Olson, Sara H.
AU - Orlow, Irene
AU - Pasquali, Claudio
AU - Patel, Alpa V.
AU - Peters, Ulrike
AU - Pezzilli, Raffaele
AU - Porta, Miquel
AU - Real, Francisco X.
AU - Rothman, Nathaniel
AU - Scelo, Ghislaine
AU - Sesso, Howard D.
AU - Severi, Gianluca
AU - Shu, Xiao Ou
AU - Silverman, Debra
AU - Smith, Jill P.
AU - Soucek, Pavel
AU - Sund, Malin
AU - Talar-Wojnarowska, Renata
AU - Tavano, Francesca
AU - Thornquist, Mark D.
AU - Tobias, Geoffrey S.
AU - Van Den Eeden, Stephen K.
AU - Vashist, Yogesh
AU - Visvanathan, Kala
AU - Vodicka, Pavel
AU - Wactawski-Wende, Jean
AU - Wang, Zhaoming
AU - Wentzensen, Nicolas
AU - White, Emily
AU - Yu, Herbert
AU - Yu, Kai
AU - Zeleniuch-Jacquotte, Anne
AU - Zheng, Wei
AU - Kraft, Peter
AU - Li, Donghui
AU - Chanock, Stephen
AU - Obazee, Ofure
AU - Petersen, Gloria M.
AU - Amundadottir, Laufey T.
N1 - Funding Information: This work was supported by RO1 CA154823, the Lustgarten Foundation, and federal funds from the NCI, US NIH under contract number HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the US Department of Health and Human Services, and mention of trade names, commercial products, or organizations does not imply endorsement by the US government. Geno-typing Services were provided by the CIDR and the NCI’s CGR. CIDR is fully funded through a federal contract from the NIH to the Johns Hopkins University, contract number HHSN268201100011I. The IARC/Central Europe study was supported by a grant from the US NCI at the NIH (R03 CA123546-02) and grants from the Ministry of Health of the Czech Republic (NR 9029-4/2006, NR9422-3, NR9998-3, and MH CZ-DRO-MMCI 00209805). The work at Johns Hopkins University was supported by the NCI Grants P50CA062924 and R01CA97075. Additional support was provided by, Susan Wojcicki, and Dennis Troper, and the Sol Goldman Pancreas Cancer Research Center. The Mayo Clinic Biospecimen Resource for Pancreas Research study is supported by the Mayo Clinic SPORE in Pancreatic Cancer (P50 CA102701). The Memorial Sloan Kettering Cancer Center Pancreatic Tumor Registry is supported by P30CA008748, the Geoffrey Beene Foundation, the Arnold and Arlene Goldstein Family, Foundation, and the Society of MSKCC. The PACIFIC Study was supported by RO1CA102765, Kaiser Permanente, and Group Health Cooperative. The Queensland Pancreatic Cancer Study was supported by a grant from the National Health and Medical Research Council of Australia (NHMRC; Grant number 442302). R.E.N. is supported by a NHMRC Senior Research Fellowship (#1060183). The UCSF pancreas study was supported by NIH-NCI grants (R01CA1009767, R01CA109767-S1, and R0CA059706) and the Joan Rombauer Pancreatic Cancer Fund. Collection of cancer incidence data was supported by the California Department of Public Health as part of the statewide cancer reporting program; the NCI’s SEER Program under contract HSN261201000140C awarded to CPIC; and the CDC’s National Program of Cancer Registries, under agreement #U58DP003862-01 awarded to the California Department of Public Health. The Yale (CT) pancreas cancer study is supported by NCI at the U.S. NIH, grant 5R01CA098870. The cooperation of 30 Connecticut hospitals, including Stamford Hospital, in allowing patient access is gratefully acknowledged. The Connecticut Pancreas Cancer Study was approved by the State of Connecticut Department of Public Health Human Investigation Committee. Certain data used in that study were obtained from the Connecticut Tumor Registry in the Connecticut Department of Public Health. The authors assume full responsibility for analyses and interpretation of these data. Studies included in PANDoRA were partly funded by the Czech Science Foundation (No. P301/12/1734), the Internal Grant Agency of the Czech Ministry of Health (IGA NT 13 263); the Baden-Württemberg State Ministry of Research, Science and Arts (Professor H. Brenner), the Heidelberger EPZ-Pancobank (Professor M.W. Büchler and team: Professor T. Hackert, Dr. N. A. Giese, Dr. Ch. Tjaden, E. Soyka, M. Meinhardt; Heidelberger. Stiftung Chir-urgie and BMBF grant 01GS08114), the BMBH (Professor P. Schirmacher; BMBF grant 01EY1101), the “5 × 1000” voluntary contribution of the Italian Government, the Italian Ministry of Health (RC1203GA57, RC1303GA53, RC1303GA54, and RC1303GA50), the Italian Association for Research on Cancer (Professor A. Scarpa; AIRC n. 12182), the Italian Ministry of Research (Professor A. Scarpa; FIRB - RBAP10AHJB), the Italian FIMP-Ministry of Health (Professor A. Scarpa; 12 CUP_J33G13000210001), and by the National Institute for Health Research Liverpool Pancreas Biomedical Research Unit, UK. We would like to acknowledge the contribution of Dr. Frederike Dijk and Professor Oliver Busch (Academic Medical Center, Amsterdam, the Netherlands). Assistance with genotype data quality control was provided by Cecelia Laurie and Cathy Laurie at the University of Washington Genetic Analysis Center. The American Cancer Society (ACS) funds the creation, maintenance, and updating of the Cancer Prevention Study II cohort. Cancer incidence data for CLUE were provided by the Maryland Cancer Registry, Center for Cancer Surveillance and Control, Department of Health and Mental Hygiene, 201 W. Preston Street, Room 400, Baltimore, MD 21201, http://phpa.dhmh.maryland.gov/ cancer, 410-767-4055. We acknowledge the State of Maryland, the Maryland Cigarette Restitution Fund, and the National Program of Cancer Registries of the Centers for Disease Control and Prevention for the funds that support the collection and availability of the cancer registry data. We thank all the CLUE participants. The Melbourne Collaborative Cohort Study (MCCS) recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants 209057 and 396414 and by the infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry and the Australian Institute of Health and Welfare, including the National Death Index and the Australian Cancer Database. The NYU study (AZJ and AAA) was funded by NIH R01 CA098661, UM1 CA182934 and center grants P30 CA016087 and P30 ES000260. The PANKRAS II Study in Spain was supported by research grants from Instituto de Salud Carlos III-FEDER, Spain: Fondo de Investigaciones Sanitarias (FIS; #PI13/00082 and #PI15/01573) and Red Temática de Investigación Cooperativa en Cáncer, Spain (#RD12/ 0036/0050); and European Cooperation in Science and Technology (COST Action #BM1204: EU_Pancreas), Ministerio de Ciencia y Tecnología (CICYT SAF 2000-0097), Fondo de Investigación Sanitaria (95/0017), Madrid, Spain; Generalitat de Catalunya (CIRIT—SGR); “Red temática de investigación cooperativa de centros en Cáncer” (C03/ 10), “Red temática de investigación cooperativa de centros en Epidemiología y salud pública” (C03/09), and CIBER de Epidemiología (CIBERESP), Madrid. The Physicians’ Health Study was supported by research grants CA-097193, CA-34944, CA-40360, HL-26490, and HL-34595 from the NIH, Bethesda, MD, USA. The Women’s Health Study was supported by research grants CA-047988, HL-043851, HL-080467, and HL-099355 from the NIH, Bethesda, MD, USA. Health Professionals Follow-up Study is supported by NIH grant UM1 CA167552 from the NCI, Bethesda, MD, USA. Nurses’ Health Study is supported by NIH grants UM1 CA186107, P01 CA87969, and R01 CA49449 from the NCI, Bethesda, MD, USA. Additional support from the Hale Center for Pancreatic Cancer Research, U01 CA21017 from the NCI, Bethesda, MD, USA, and the United States Department of Defense CA130288, Lustgarten Foundation, Pancreatic Cancer Action Network, Noble Effort Fund, Peter R. Leavitt Family Fund, Wexler Family Fund, and Promises for Purple to B.M. Wolpin is acknowledged. The WHI program is funded by the National Heart, Lung, and Blood Institute, NIH, U.S. Department of Health and Human Services through contracts HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C. The authors thank the WHI investigators and staff for their dedication, and the study participants for making the program possible. A full listing of WHI investigators can be found at http:// www.whi.org/researchers/Documents%20%20Write%20a%20Paper/WHI% 20Investigator%20Long%20List.pdf. We thank Laurie Burdett, Aurelie Vogt, Belynda Hicks, Amy Hutchinson, Meredith Yeager, and other staff at the NCI’s Division of Epidemiology and Genetics (DECG) CGR for GWAS genotyping. We also thank Bao Tran, Jyoti Shetty, and other members of the NCI Center for Cancer Research (CCR) Sequencing Facility for sequencing RNA from histologically normal pancreatic tissue samples (LTG samples). This study utilized the high-performance computational capabilities of the Biowulf Linux cluster at the NIH, Bethesda, MD, USA (http://biowulf.nih. gov). The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the NIH, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. The data used for the analyses described in this manuscript were obtained from the pancreatic tissue data from the GTEx Portal on 05/04/17. The results published here are in part based upon data generated by The Cancer Genome Atlas (TCGA) managed by the NCI and NHGRI. Information about TCGA can be found at http://cancergenome.nih.gov/. We acknowledge the clinical contributors that provided PDAC samples and the data producers of RNA-seq and GWAS genotype data from TCGA Research Network. The data set used for the analyses described in this manuscript was obtained by formal permission through the TCGA Data Access Committee (DAC). Publisher Copyright: © 2018 The Author(s).
PY - 2018/12/1
Y1 - 2018/12/1
N2 - In 2020, 146,063 deaths due to pancreatic cancer are estimated to occur in Europe and the United States combined. To identify common susceptibility alleles, we performed the largest pancreatic cancer GWAS to date, including 9040 patients and 12,496 controls of European ancestry from the Pancreatic Cancer Cohort Consortium (PanScan) and the Pancreatic Cancer Case-Control Consortium (PanC4). Here, we find significant evidence of a novel association at rs78417682 (7p12/TNS3, P = 4.35 × 10-8). Replication of 10 promising signals in up to 2737 patients and 4752 controls from the PANcreatic Disease ReseArch (PANDoRA) consortium yields new genome-wide significant loci: Rs13303010 at 1p36.33 (NOC2L, P = 8.36 × 10-14), rs2941471 at 8q21.11 (HNF4G, P = 6.60 × 10-10), rs4795218 at 17q12 (HNF1B, P = 1.32 × 10-8), and rs1517037 at 18q21.32 (GRP, P = 3.28 × 10-8). rs78417682 is not statistically significantly associated with pancreatic cancer in PANDoRA. Expression quantitative trait locus analysis in three independent pancreatic data sets provides molecular support of NOC2L as a pancreatic cancer susceptibility gene.
AB - In 2020, 146,063 deaths due to pancreatic cancer are estimated to occur in Europe and the United States combined. To identify common susceptibility alleles, we performed the largest pancreatic cancer GWAS to date, including 9040 patients and 12,496 controls of European ancestry from the Pancreatic Cancer Cohort Consortium (PanScan) and the Pancreatic Cancer Case-Control Consortium (PanC4). Here, we find significant evidence of a novel association at rs78417682 (7p12/TNS3, P = 4.35 × 10-8). Replication of 10 promising signals in up to 2737 patients and 4752 controls from the PANcreatic Disease ReseArch (PANDoRA) consortium yields new genome-wide significant loci: Rs13303010 at 1p36.33 (NOC2L, P = 8.36 × 10-14), rs2941471 at 8q21.11 (HNF4G, P = 6.60 × 10-10), rs4795218 at 17q12 (HNF1B, P = 1.32 × 10-8), and rs1517037 at 18q21.32 (GRP, P = 3.28 × 10-8). rs78417682 is not statistically significantly associated with pancreatic cancer in PANDoRA. Expression quantitative trait locus analysis in three independent pancreatic data sets provides molecular support of NOC2L as a pancreatic cancer susceptibility gene.
UR - http://www.scopus.com/inward/record.url?scp=85041960929&partnerID=8YFLogxK
U2 - 10.1038/s41467-018-02942-5
DO - 10.1038/s41467-018-02942-5
M3 - Article
AN - SCOPUS:85041960929
SN - 2041-1723
VL - 9
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 556
ER -